The ACER1 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population in which the ACER1 gene has been disrupted to abrogate alkaline ceramidase activity. This loss-of-function model is generated in the human 143B osteosarcoma cell line, providing a genetically heterogeneous knockout pool suitable for studying sphingolipid-mediated processes in a bone cancer context. The polyclonal format preserves a range of editing events across the cell population, enabling robust functional studies without the clonal selection bias often associated with monoclonal lines. This product serves as a versatile tool for investigating ACER1-dependent mechanisms in apoptosis, proliferation, and drug response.
The 143B cell line is a tumorigenic subclone of the HOS human osteosarcoma lineage, widely utilized for bone cancer research. These osteoblastic cells retain key features of osteosarcoma pathology, including aggressive growth and metastatic potential. 143B cells are particularly valued for their reproducible in vitro and in vivo tumorigenic properties, making them an ideal host for genetic manipulation aimed at dissecting oncogenic signaling networks. Their well-characterized background facilitates the interpretation of ACER1 knockout phenotypes in the context of osteosarcoma biology.
ACER1 encodes an alkaline ceramidase that catalyzes the hydrolysis of ceramides into sphingosine and free fatty acids, a critical step in sphingolipid metabolism. The enzyme functions downstream of ceramide synthases and sphingomyelinases, and its activity governs the balance between pro-apoptotic ceramide and pro-survival sphingosine-1-phosphate (S1P). ACER1 is regulated by upstream factors such as TNF-alpha, p53, and oxidative stress, while its product sphingosine is further phosphorylated by sphingosine kinases (SPHK1, SPHK2) to generate S1P, which signals through S1P receptors. Interacting partners include ceramide synthases and sphingomyelinases, placing ACER1 at a nodal point of the sphingolipid rheostat. Disruption of ACER1 thus perturbs this equilibrium, leading to ceramide accumulation and diminished sphingosine/S1P pools, with consequent impacts on downstream targets like S1P receptors and SPHKs.
In the 143B osteosarcoma background, ACER1 knockout abrogates alkaline ceramidase activity, resulting in elevated ceramide levels and reduced sphingosine production. This imbalance disrupts sphingolipid-mediated control of cell fate, skewing the rheostat toward ceramide-driven apoptosis or, paradoxically, promoting adaptive survival mechanisms under certain conditions. The model allows for dissection of how sphingolipid signaling modulates osteosarcoma cell proliferation, differentiation, and tumorigenicity, particularly in the context of bone microenvironment interactions. Since osteosarcoma cells often exhibit dysregulated sphingolipid metabolism, ACER1 knockout provides a defined genetic perturbation to probe ceramide/S1P signaling contributions to malignancy and therapy resistance.
Researchers can employ these polyclonal knockout cells for a variety of investigative purposes, including sphingolipid metabolism studies using LC-MS quantification of ceramide and sphingosine species, apoptosis assays with Annexin V/PI staining, and cell proliferation analysis by MTT assay. The model is also suited for drug sensitivity screening, where the impact of ACER1 disruption on chemotherapeutic response can be evaluated. Western blotting and RT-qPCR enable validation of pathway component expression changes, while sphingosine kinase activity assays offer functional readouts of S1P generation. These applications facilitate deep exploration into ceramide signaling and its interplay with tumorigenic processes in osteosarcoma. For further technical information, please contact Ascent Research.
